レジメンチニブは、攻撃的な上皮がんの再利用のためにトランスクリプトームガイド薬を特定しました
Sonja Dorfer1, Roland Zauner1, Christina Guttmann-Gruber1
1EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, Austria.
The Journal of investigative dermatology
|December 21, 2025
まとめ
MEK阻害剤であるレジメンチニブは、劣性ジストロフィック表皮水疱症(RDEB-SCC)の攻撃的な扁平上皮癌の治療に有望です。この候補薬は、前臨床研究で腫瘍の成長と浸潤を効果的に減少させました。
関連する概念動画
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K


